Literature DB >> 10235418

Autoimmune thyroiditis and myelosuppression following treatment with interferon-alpha for hepatitis C.

K Schmitt1, B C Hompesch, K Oeland, W G von Staehr, P A Thürmann.   

Abstract

CASE: We describe the case of a 48-year-old woman from Thailand diagnosed with chronic hepatitis C, who experienced a suppression of all blood cell counts accompanied by a newly developed clinically manifested autoimmune thyroid disorder after treatment with interferon alpha-2b (INF-alpha) 46 days after beginning of therapy a decrease of platelet, red and white blood cell counts became obvious. Concomitantly we observed an increase of FT4 and FT3 with a totally depressed TSH level 80 days after starting INF-alpha administration. Antibody assessment resulted in detection of high numbers of antithyroid-microsomal antibodies and antithyroglobulin antibodies. Thyroid hormone levels normalized under treatment with methimazole/propylthiouracil within 4.5 months. However, two months after cessation of antithyroid therapy increasing TSH levels and decreasing FT4 levels indicated a new tendency towards a hypothyroid state.
CONCLUSION: We classify this case as an interferon-alpha-induced disorder of thyroid function accompanied by myelosuppression. A close monitoring for thyroid dysfunction, e.g. evaluation of TSH-levels before and after administration of INF-alpha is mandatory.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235418

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  1 in total

1.  Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection.

Authors:  Steve Searles; Katherine Gauss; Michelle Wilkison; Teri R Hoyt; Erin Dobrinen; Nicole Meissner
Journal:  J Immunol       Date:  2013-08-23       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.